MEHTA VIMAL (CEO, President, Secretary) sold 21.8% of their position (19.42K shares) of BIOXCEL THERAPEUTICS, INC. on the open market
Open‑market sale worth $21.1K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 5/22/2026ACC: 0001104659-26-065836
DirectorOfficer· CEO, President, Secretary
Since Nov 2018
-19.42K
Net shares
Net seller
$21.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
49.76K acquired · 69.18K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+49.76K
Price / share
—
Trade value
—
% of position
126.7%
5/4/2026
39.26K→89.02K
Common Stock
Direct
Shares
−19.42K
Price / share
$1.09
Trade value
$21.11K
% of position
21.8%
5/20/2026
89.02K→69.60K
Total
Net shares
+30.34K
Net value
-$21.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/4/2026 | M · Option Exercise | +49.76K | — | — | 126.7% | 39.26K | 89.02K |
| Common Stock Direct | 5/20/2026 | S · Sale | −19.42K | $1.09 | $21.11K | 21.8% | 89.02K | 69.60K |
| Total | +30.34K | -$21.11K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
49.76K shares
Shares
−49.76K
Strike price
Held after
149.27K
Exercisable
—
5/4/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock49.76K shares | 5/4/2026 | M · Option Exercise | −49.76K | — | 149.27K |
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned480.34K
Common Stock
IndirectShares owned125.00
Total
480.47K indirect480.47K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 480.34K | Indirect |
| Common Stock | 125.00 | Indirect |
| Total | 480.47K | 480.47K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported